The IVD (in vitro diagnostics) quality control market encompasses the sector focused on providing quality control materials, reference standards, calibration tools, data management software, and quality assurance services used to ensure the accuracy, precision, and reliability of diagnostic laboratory testing. It serves clinical laboratories, hospitals, diagnostic centers, and research institutions across platforms like immunoassays, clinical chemistry, hematology, and molecular diagnostics.
The global IVD quality controls market was valued at USD 1.58 billion in 2024 and USD 1.65 billion in 2025, and it is projected to reach USD 2.15 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.5%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582
The IVD quality control and treatment market is primarily driven by the rising global volume of clinical laboratory testing, increasing prevalence of chronic and infectious diseases, and stringent mandatory accreditation standards requiring regular quality assurance. However, market expansion is significantly restrained by the high cost of automated quality control systems, complex multi-regional regulatory compliance pathways, and widespread pricing pressure on healthcare spending. Lucrative opportunities lie in the rapid expansion of point-of-care (PoC) testing, the integration of cloud-based informatics and AI-driven predictive QC platforms, and increasing demand for specialized controls in high-complexity testing modalities like next-generation sequencing. Despite these prospects, the market faces key challenges, including severe supply chain vulnerabilities affecting reagent availability, localized reimbursement limitations, and high capital investment requirements that hinder adoption within resource-limited and decentralized healthcare settings.
Target customers for the IVD quality treatment and controls market encompass institutional healthcare providers, clinical diagnostic laboratories, hospital pathology departments, reference labs, and IVD equipment manufacturers. These entities require high-precision quality control (QC) materials, calibration standards, micro-fluidic controls, and assay validation kits to maintain strict analytical accuracy, ensure compliance with evolving global regulations (such as ISO 15189 standards and the FDA QMSR framework), and avoid costly false diagnoses. Institutional buyers prioritize lot-to-lot consistency, extended shelf life, third-party independence, seamless integration with automated laboratory information management systems (LIMS), and proven cost-effectiveness to mitigate operational expenses. Purchasing behavior is heavily structured and risk-averse, typically characterized by multi-year procurement contracts, bundled reagent-and-control rental agreements, and stringent vendor evaluations focused on regulatory compliance and reliable supply chain delivery.
Market entry, expansion, and profitability in the IVD quality control and treatment market are heavily governed by stringent regulatory frameworks, continuous technological advancements, and key economic dynamics. Regulators such as the U.S. FDA, European Union (under IVDR 2017/746), and India’s CDSCO enforce rigorous risk-based classifications, ISO 13485 quality system standards, and extensive performance evaluations, which ensure high clinical accuracy but raise entry barriers and compliance costs for manufacturers. Technologically, the sector is experiencing significant disruption from the integration of automated liquid handling, cloud-connected quality control platforms, AI-driven predictive analytics, and point-of-care (PoC) diagnostic monitoring tools that streamline laboratory workflows and minimize human error. Economically, while increasing chronic disease prevalence, expanding global laboratory infrastructure, and rising accreditation requirements drive steady demand for quality controls, market profitability remains constrained by high capital investments for automated systems, localized pricing controls, fragmented reimbursement structures, and supply chain vulnerabilities impacting reagent availability.
The in-vitro diagnostics (IVD) quality control market is being rapidly transformed by the shift toward automated, decentralized, and highly integrated diagnostic care. Emerging trends are dominated by the growing reliance on independent third-party quality controls, the integration of artificial intelligence for automated trend analysis and predictive quality assurance, and the rapid expansion of point-of-care (POC) testing and molecular diagnostics in decentralized settings. Additionally, diagnostic laboratories are increasingly adopting multi-analyte liquid controls, continuous cloud-connected quality monitoring systems, and external quality assessment (EQA) programs to ensure stringent regulatory compliance and maintain cross-platform accuracy. These trends are evolving at a steady to rapid pace, reflected by expanding accredited laboratory networks globally and a solid market growth rate projected at a CAGR of 5% to 5.5%, propelled by rising clinical testing volumes and the continuous modernization of diagnostic infrastructure.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582
Technological innovations disrupting the in vitro diagnostics (IVD) quality control market are focused on automation, digital health integration, and advanced molecular monitoring solutions. The industry is seeing rapid adoption of automated data management software and cloud-based informatics platforms, which enable real-time quality control tracking, trend analysis, and automated risk flagging to minimize human error and streamline laboratory workflows. Additionally, the expansion of point-of-care (POC) testing and decentralized care models is driving demand for compact, multianalyte controls and digital tools capable of remote, continuous monitoring. The integration of artificial intelligence and predictive analytics, alongside specialized reference standards for high-complexity modalities like next-generation sequencing (NGS) and digital PCR, is further enhancing analytical precision and operational efficiency across clinical laboratories.
In the IVD quality and diagnostics market, short-term trends are primarily driven by temporary surge demand for rapid single-use testing kits during acute infectious disease outbreaks, localized procurement surges, and initial social media hype around unvalidated direct-to-consumer wellness gadgets. Conversely, long-term structural shifts are firmly anchored in enduring healthcare modernization and regulatory enforcement. These permanent transformations include the transition from centralized laboratory testing toward point-of-care (PoC) and home-based diagnostics, the integration of artificial intelligence and cloud-based middleware for real-time quality control, and stricter compliance mandates (such as ISO standards and FDA oversight) aimed at ensuring diagnostic accuracy across decentralized clinical settings.
